Oncternal Therapeutics, Inc.

ONCT · NASDAQ
Analyze with AI
9/30/2024
6/30/2024
3/31/2024
12/31/2023
Operating Activities
Net Income-$8,464-$8,559-$8,388-$9,164
Dep. & Amort.$0$0$0$329
Deferred Tax$0$0$0$112
Stock-Based Comp.$1,854$1,382$1,360$2,218
Change in WC-$1,404$1,539-$135$869
Other Non-Cash$1,061$757$771-$342
Operating Cash Flow-$6,953-$5,822-$7,438-$6,419
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$6,292-$10,026-$11,808
Inv. Sales/Matur.$13,650$12,100$17,250$10,000
Other Inv. Act.$0$5,808$7,224-$1,808
Investing Cash Flow$13,650$5,808$7,224-$1,808
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$0
Stock Repurch.$0$0-$87-$1
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$0$0-$87-$1
Forex Effect$0$0$0$2,581
Net Chg. in Cash$6,697-$14-$301-$8,228
Supplemental Information
Beg. Cash$6,382$6,396$6,697$14,925
End Cash$13,079$6,382$6,396$6,697
Free Cash Flow-$6,953-$5,822-$7,438-$6,419
Oncternal Therapeutics, Inc. (ONCT) Financial Statements & Key Stats | AlphaPilot